Market Recap: Markets Mixed, Tiffany Sparkles, Nokia Pops

Markets closed mixed on Wall Street today: Dow -0.25%, S&P -0.05%, Nasdaq +0.11%, Oil -0.46%, Gold -0.42%.

On the commodities front, Oil (NYSE:USO) declined to $95.75 a barrel. Precious metals were mixed, with Gold (NYSE:GLD) falling to $1,666 an ounce while Silver (NYSE:SLV) rose 0.04 to settle at $30.66.

Here’s your Cheat Sheet to today’s top stock stories:

A high-resolution display bound for a rumored 13-inch MacBook Pro (NASDAQ:AAPL) with Retina display is now in production, according to an analyst citing upstream supply chain sources, with initial output volumes expected to be higher than the current 15-inch version. According to NPD DisplaySearch analyst Richard Shim, the display purportedly being produced for the smallest MacBook Pro has a resolution of 2,560-by-1600 pixels, compared to the current version’s 1,280-by-800 pixel screen.

Meanwhile, Apple’s shares continued to rise after Friday’s Samsung verdict and on Monday, it hit a new high of $680.87.

Nokia Corp.’s (NYSE:NOK) shares rose 8 percent after analysts said the company could see a rise in sales after Friday’s federal jury ruling against rival Samsung Electronics Co.

Kenexa Corp.’s (NASDAQ:KNXA) shares jumped 42 percent. This came after International Business Machines Corp. (NYSE:IBM) announced it  would acquire the company for $46 per share, or about $1.3 billion.

Tiffany & Co.’s (NYSE:TIF) shares increased 7.6 percent after the company cut its fiscal-year sales and profit outlooks. This came in less than what many had anticipated. One analyst noted, “They missed on the top and bottom line, and yet the stock is up, which is counter to what one would have anticipated, but expectations were for a much bigger miss.”

Sarepta Therapeutics Inc. (SRPT) shares rose 13 percent after ThinkEquity began coverage with a “Buy” rating. Over the weekend, a  Barron’s story emphasized the one of company’s developing drug may provide an inaugural effective treatment for the severest form of muscular dystrophy.